MONTRÉAL, Feb.25, 2019 /CNW Telbec/ - On February 21st, in Montréal, a launch cocktail took place for the second cohort of the Life Sciences Entrepreneurship Development Program, where IRICoR and the Oncopole announced the awarding of 9 scholarships to graduate students and postdoctoral fellows in the field of oncology research.
Organized jointly by the three founding partners of the Program: Montréal InVivo, Université de Montréal's Faculty of Pharmacy and Concordia University's John Molson Executive Centre, in collaboration with IRICoR, the event brought together more than 40 people.
For a second year, IRICoR and the Oncopole joined forces to support the next generation of scientists through the Scholarship Competition – Entrepreneurship in Oncology (CEO). They offer opportunities to young scientists to take part in the Life Sciences Entrepreneurship Development Program. This practical and immersive program, divided into 10 intensive two-day modules, includes more than 150 hours of strategic content. The first edition proved to be a real success with participating students.
For a second year in a row, IRICoR is proud to join the efforts deployed by Montréal InVivo, Université de Montréal's Faculty of Pharmacy and Concordia University's John Molson Executive Centre, by proposing a day focused on "Drug Development in Oncology" to further develop the formula.
At the launch party of the 2nd cohort of the Program, Nadine Beauger, IRICoR's Chief Executive Officer, congratulated the recipients of the CEO scholarships. She was delighted that IRICoR is contributing tangibly to the training of the next generation of scientists. "The development of entrepreneurial skills is at the heart of the future of our sector. I am convinced that the 19 participants of this new cohort will benefit from the unique expertise available to them and that it will enable them to be truly sensitized to the needs and issues of the field."
For more information about the program, click here.
About IRICoR
As a project maturation cluster in the field of drug discovery, IRICoR is a not-for-profit organization based at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal. IRICoR's mandate is to accelerate the discovery, development, and commercialization of novel therapies in cancer, immunotherapy, and related fields. Since 2008, IRICoR has been successfully investing in and supporting selected cutting-edge projects in order to rapidly translate early-stage innovation into potential new therapies, through either co-development partnerships with the biopharmaceutical industry or the creation of spin-off companies. IRICoR seamlessly integrates its business-related expertise with access to industry-level drug discovery capabilities, providing selected academic and industry projects with access to its network of experts and cutting-edge infrastructure, including one of the largest academia-based medicinal chemistry groups in Canada. IRICoR's major funding sources include the Centres of Excellence for Commercialization and Research (CECR) program of the Canadian government, the Ministère de l'Économie, de la Science et de l'Innovation du Québec (MESI), and collaborative partnerships with the biopharmaceutical industry.
For more information about IRICoR: iricor.ca
SOURCE IRICOR
Alix Molinier, Project Manager, IRICoR, 514-343-6111 ext. 0324, [email protected]; Catherine Cardinal, Director, Communication and Media Relations, IRICoR, 514-343-6111, ext. 41299, [email protected]
Share this article